Fig. 2: Evaluation of quantitative range and sensitivity of MRD assays specific for gene fusions, clonal Ig/TCR rearrangements and recurrent IKZF1 deletions.
a 21 patients with the ABL-class fusions shown in Table 1 and (b) 44 BCR-ABL1 patients. B-A denotes data for BCR-ABL1 fusion assays.
